Products
Data
Feature
Plans
Request Demo
Sign Up for Free
Blog
Valuable Targets
Advanced Tech.
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
CDH9 Biologics Sequence Review Report 2026: Cadherin-9 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of CDH9 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
8 min read
CDHR1 Biologics Sequence Review Report 2026: Cadherin-related family member 1 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of CDHR1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
8 min read
CDH7 Biologics Sequence Review Report 2026: Cadherin-7 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of CDH7 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
8 min read
CDH6 Biologics Sequence Review Report 2026: Cadherin-6 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of CDH6 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
8 min read
CDH26 Biologics Sequence Review Report 2026: Cadherin-like protein 26 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of CDH26 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
8 min read
CDH5 Biologics Sequence Review Report 2026: Cadherin-5 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of CDH5 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
8 min read
CDH3 Biologics Sequence Review Report 2026: Cadherin-3 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of CDH3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
8 min read
CDH24 Biologics Sequence Review Report 2026: Cadherin-24 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of CDH24 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
8 min read
CDH20 Biologics Sequence Review Report 2026: Cadherin-20 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of CDH20 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
8 min read
CDH19 Biologics Sequence Review Report 2026: Cadherin-19 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of CDH19 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
8 min read
CDH22 Biologics Sequence Review Report 2026: Cadherin-22 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of CDH22 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
8 min read
CDH17 Biologics Sequence Review Report 2026: Cadherin-17 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of CDH17 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
<
1
<<
4
5
6
7
8
>>
1503
>